Ascletis Subsidiary OK'd to Start US Trials of NASH Candidate
publication date: Oct 12, 2020
An Ascletis Pharma subsidiary, Gannex Pharma, was approved to begin US clinical trials of its novel candidate for non-alcoholic steatohepatitis (NASH). Developed in-house, ASC42 is a non-steroidal, selective Farnesoid X Receptor (FXR) agonist that Gannex believes has best-in-class potential. The candidate is one of three potential treatments that Ascletis is developing for NASH. Gannex said ASC42 demonstrated significant improvements in liver steatosis, inflammation and fibrosis in animal models of NASH. More details....
Stock Symbol: (HKEX: 1672)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.